Company intelligence / Profile preview

TES-ONC

Corciano, Umbria, Italy

Ownership: Private
Development stage: Other

Overview

TES-ONC is a biotechnology company focused on the discovery and development of novel small molecule therapeutics for the treatment of cancer. The company specializes in targeting the kynurenine pathway, which plays a critical role in immune evasion by tumors. By developing potent inhibitors of enzymes such as KMO, IDO1, and TDO, TES-ONC aims to restore the immune system's ability to recognize and destroy malignant cells. The company operates as a spin-off or specialized oncology-focused entity related to the broader TES Pharma research organization.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on TES-ONC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TES-ONC.

Explore the full profile